Oncology ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad In a conversation at ASCO 2026, Dr Fred Saad of the University of Montreal shared some insights from a subgroup analysis of Pluvicto
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Patients ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.
Oncology ASCO 2026: Three ADC approvals in five days, with Ken Keller... At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
